Serum Institute to manufacture NOVAVAX Vaccine
Date -15th Jun 2021
US biotechnology company NOVAVAX announced on June 14, 2021 that its COVID-19 vaccine provides 100% protection against moderate to severe disease symptoms and has shown an overall 90.4% efficacy in phase 3 trials. Speaking about the results of clinical trials, the President and Chief Executive Officer NOVAVAX CEO Stanley Eric said NOVAVAX is now one step closer to addressing the urgent and ongoing public health need for additional vaccines.
Click on the image to view the official tweet
The NOVAVAX COVID-19 vaccine, NVX-CoV2373, may be a candidate for protein vaccines. It is based on the genetic sequence of the primary strain of SARS-CoV-2, the virus that caused COVID-19. In a Phase 3 trial, NOVAVAX enrolled 29,960 participants at 119 centers in the United States and Mexico to evaluate the safety, efficacy, and immunogenicity of the vaccine. Emphasis has also been placed on recruiting a representative population from the communities and demographics most affected by COVID-19.
In terms of vaccination rates, these countries lag significantly behind the industrialized nations of the Group of Seven and other wealthy nations. In terms of doses administered so far, the imbalance between low-income countries and the G7 countries is 73 to one, according to the World Bank.
The Serum Institute will produce the NOVAVAX vaccine
In 2020, NOVAVAX announced an amendment to its existing agreement with the Serum Institute of India under which SII will also produce the antigenic component of NVX-CoV2373, the COVID-19 candidate vaccine from NOVAVAX.
For more Updates and Information - Click here
For access to more than 10,000 Colleges - Click here
For Latest Sarkari Jobs - Click here
For Comprehensive Preparation of Competitive Exams - Click here
For School Studies and Exams Preparation across Eight Boards - Click here
News about the latest admissions, results, upcoming government jobs, Sarkari exams and many more.